Disease progression modeling of Alzheimer's disease according to education level

被引:19
|
作者
Kim, Ko Woon [1 ,2 ,3 ,4 ]
Woo, Sook Young [5 ]
Kim, Seonwoo [5 ]
Jang, Hyemin [1 ,6 ]
Kim, Yeshin [1 ,7 ]
Cho, Soo Hyun [1 ,8 ]
Kim, Si Eun [1 ,9 ]
Kim, Seung Joo [1 ,10 ,11 ]
Shin, Byoung-Soo [2 ,3 ,4 ]
Kim, Hee Jin [1 ,6 ]
Na, Duk L. [1 ,6 ,12 ,13 ]
Seo, Sang Won [1 ,12 ,13 ,14 ]
机构
[1] Sungkyunkwan Univ, Dept Neurol, Samsung Med Ctr, Sch Med, 81 Irwon Dong, Seoul 06351, South Korea
[2] Jeonbuk Natl Univ Hosp, Sch Med, Dept Neurol, Jeonju, South Korea
[3] Jeonbuk Natl Univ, Res Inst Clin Med, Jeonju, South Korea
[4] Jeonbuk Natl Univ Hosp, Biomed Inst, Jeonju, South Korea
[5] Samsung Med Ctr, Stat & Data Ctr, Seoul, South Korea
[6] Samsung Med Ctr, Neurosci Ctr, Seoul, South Korea
[7] Kangwon Natl Univ, Kangwon Natl Univ Hosp, Dept Neurol, Coll Med, Chunchon, South Korea
[8] Chonnam Natl Univ, Dept Neurol, Med Sch & Hosp, Gwangju, South Korea
[9] Inje Univ, Haeundae Paik Hosp, Dept Neurol, Coll Med, Busan, South Korea
[10] Gyeongsang Natl Univ, Dept Neurol, Sch Med, Chang Won, South Korea
[11] Gyeongsang Natl Univ, Changwon Hosp, Chang Won, South Korea
[12] Sungkyunkwan Univ, Dept Hlth Sci & Technol, SAIHST, Seoul, South Korea
[13] Samsung Med Ctr, Samsung Alzheimer Res Ctr, Seoul, South Korea
[14] Sungkyunkwan Univ, Dept Intelligent Precis Healthcare Convergence, Sch Med, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
MILD COGNITIVE IMPAIRMENT; DECLINE; DEMENTIA; DIAGNOSIS; SCALE;
D O I
10.1038/s41598-020-73911-6
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
To develop a disease progression model of Alzheimer's disease (AD) that shows cognitive decline from subjective cognitive impairments (SCI) to the end stage of AD dementia (ADD) and to investigate the effect of education level on the whole disease spectrum, we enrolled 565 patients who were followed up more than three times and had a clinical dementia rating sum of boxes (CDR-SB). Three cohorts, SCI (n=85), amnestic mild cognitive impairment (AMCI, n=240), and ADD (n=240), were overlapped in two consecutive cohorts (SCI and AMCI, AMCI and ADD) to construct a model of disease course, and a model with multiple single-cohorts was estimated using a mixed-effect model. To examine the effect of education level on disease progression, the disease progression model was developed with data from lower (<= 12) and higher (>12) education groups. Disease progression takes 274.3 months (22.9 years) to advance from 0 to 18 points using the CDR-SB. Based on our predictive equation, it takes 116.5 months to progress from SCI to AMCI and 56.2 months to progress from AMCI to ADD. The rate of CDR-SB progression was different according to education level. The lower-education group showed faster CDR-SB progression from SCI to AMCI compared to the higher-education group, and this trend disappeared from AMCI to ADD. In the present study, we developed a disease progression model of AD spectrum from SCI to the end stage of ADD. Our disease modeling provides us with more understanding of the effect of education on cognitive trajectories.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Slowing progression of Alzheimer's disease
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (02) : 185 - 185
  • [32] Metabolome in progression to Alzheimer's disease
    Oresic, M.
    Hyotylainen, T.
    Herukka, S-K
    Sysi-Aho, M.
    Mattila, I.
    Seppanan-Laakso, T.
    Julkunen, V.
    Gopalacharyulu, P. V.
    Hallikainen, M.
    Koikkalainen, J.
    Kivipelto, M.
    Helisalmi, S.
    Lotjonen, J.
    Soininen, H.
    TRANSLATIONAL PSYCHIATRY, 2011, 1 : e57 - e57
  • [33] Slowing the progression of Alzheimer's disease
    Laffman, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (05) : 656 - 656
  • [34] Halting the progression of Alzheimer's disease
    Houlton, S
    MANUFACTURING CHEMIST, 2001, 72 (09): : 18 - 20
  • [35] Predicting progression of Alzheimer's disease
    Doody, Rachelle S.
    Pavlik, Valory
    Massman, Paul
    Rountree, Susan
    Darby, Eveleen
    Chan, Wenyaw
    ALZHEIMERS RESEARCH & THERAPY, 2010, 2 (01):
  • [36] Modeling Disease Progression via Multisource Multitask Learners: A Case Study With Alzheimer's Disease
    Nie, Liqiang
    Zhang, Luming
    Meng, Lei
    Song, Xuemeng
    Chang, Xiaojun
    Li, Xuelong
    IEEE TRANSACTIONS ON NEURAL NETWORKS AND LEARNING SYSTEMS, 2017, 28 (07) : 1508 - 1519
  • [37] Disease progression timeline estimation for Alzheimer's disease using discriminative event based modeling
    Venkatraghavan, Vikram
    Bron, Esther E.
    Niessen, Wiro J.
    Klein, Stefan
    Weiner, Michael W.
    Aisen, Paul
    Weiner, Michael
    Petersen, Ronald
    Jack, Clifford R., Jr.
    Jagust, William
    Trojanowki, John Q.
    Toga, Arthur W.
    Green, Robert C.
    Saykin, Andrew J.
    Morris, John
    Shaw, Leslie M.
    Khachaturian, Zaven
    Sorensen, Greg
    Carrillo, Maria
    Kuller, Lew
    Raichle, Marc
    Paul, Steven
    Davies, Peter
    Fillit, Howard
    Hefti, Franz
    Holtzman, David
    Mesulam, M. Marcel
    Potter, William
    Snyder, Peter
    Montine, Tom
    Jimenez, Gustavo
    Donohue, Michael
    Gessert, Devon
    Harless, Kelly
    Salazar, Jennifer
    Cabrera, Yuliana
    Walter, Sarah
    Hergesheimer, Lindsey
    Beckett, Laurel
    Harvey, Danielle
    Bernstein, Matthew
    Fox, Nick
    Thompson, Paul
    Schuff, Norbert
    DeCArli, Charles
    Borowski, Bret
    Gunter, Jeff
    Senjem, Matt
    Vemuri, Prashanthi
    Jones, David
    NEUROIMAGE, 2019, 186 : 518 - 532
  • [38] Autonomic dysfunction according to disease progression in Parkinson's disease
    Kim, Jung Bin
    Kim, Byung-Jo
    Koh, Seong-Beom
    Park, Kun-Woo
    PARKINSONISM & RELATED DISORDERS, 2014, 20 (03) : 303 - 307
  • [39] Association of peripheral blood DNA methylation level with Alzheimer's disease progression
    Li, Qingqin S.
    Vasanthakumar, Aparna
    Davis, Justin W.
    Idler, Kenneth B.
    Nho, Kwangsik
    Waring, Jeffrey F.
    Saykin, Andrew J.
    CLINICAL EPIGENETICS, 2021, 13 (01)
  • [40] Association of peripheral blood DNA methylation level with Alzheimer’s disease progression
    Qingqin S. Li
    Aparna Vasanthakumar
    Justin W. Davis
    Kenneth B. Idler
    Kwangsik Nho
    Jeffrey F. Waring
    Andrew J. Saykin
    Clinical Epigenetics, 2021, 13